Moderna Inc
Change company Symbol lookup
Select an option...
MRNA Moderna Inc
MUSA Murphy Usa Inc
SCL Stepan Co
GRWG GrowGeneration Corp
ROG Rogers Corp
ALB Albemarle Corp
DD Dupont De Nemours Inc
SMG Scotts Miracle-Gro Co
MTX Minerals Technologies Inc
HUN Huntsman Corp
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.

Closing Price
$176.40
Day's Change
-0.41 (-0.23%)
Bid
--
Ask
--
B/A Size
--
Day's High
179.14
Day's Low
173.41
Volume
(Light)
Volume:
1,221,141

10-day average volume:
3,746,478
1,221,141

Moderna Inc. Stock Underperforms Thursday When Compared To Competitors

4:32 pm ET September 29, 2022 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Moderna Inc. (MRNA) slid 3.34% to $118.07 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index falling 2.84% to 10,737.51 and Dow Jones Industrial Average falling 1.54% to 29,225.61. This was the stock's second consecutive day of losses. Moderna Inc. closed $272.53 below its 52-week high ($390.60), which the company achieved on September 30th.

The stock underperformed when compared to some of its competitors Thursday, as AbbVie Inc. (ABBV) fell 1.30% to $142.72, Amgen Inc. (AMGN) fell 1.11% to $228.41, and AstraZeneca PLC ADR (AZN.LN) rose 0.40% to $54.91. Trading volume (4.7 M) remained 32,345 below its 50-day average volume of 4.7 M.

Data source: Dow Jones Market Data, FactSet. Data compiled September 29, 2022.

	

(END) Dow Jones Newswires

September 29, 2022 16:32 ET (20:32 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.